Marea Therapeutics presented positive data from the Phase 2a clinical trial of its fat-targeting monoclonal antibody, MAR001, that could help address lipid and metabolic drivers of ASCVD.
- Originally developed by Novartis, MAR001 targets the ANGPTL4 protein in body fat tissue, which helps it lower remnant cholesterol and triglycerides in the blood.
To assess MAR001’s impact on remnant cholesterol and triglycerides, researchers randomized 55 patients with hypertriglyceridemia to one of three doses (150, 300, and 450mg) or placebo and found…
- An overall -52.5% mean reduction in remnant cholesterol and up to a -52.7% mean reduction in triglycerides at 12 weeks.
- Even greater reductions in remnant cholesterol and triglycerides (-66% and -64%) for patients with triglyceride levels ≥200 mg/dL at baseline.
These results help continue the momentum for Marea as it now plans to move MAR001 into Phase 2b trials in the second quarter of this year to evaluate its impact on metabolic dysfunction.
The Takeaway
Over five million cardiovascular patients in the U.S. have elevated remnant cholesterol, yet no approved treatment exists, so Marea’s consistent and positive results are a win, even if it takes time to get to market.
We’re testing a new format today – let us know if you prefer two shorter Top Stories or one longer Top Story with this quick survey!
